Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia

Submitted: 6 April 2020
Accepted: 28 April 2020
Published: 29 April 2020
Abstract Views: 2543
PDF: 1433
HTML: 98
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus itself, but by an overactive inflammatory state. In fact, in some people the immune system goes into overdrive and launches a large-scale assault on the tissue known as cytokine storm. This excessive inflammatory/immune reaction can damage tissue and eventually kill people. Evidence shows that blocking such cytokine storms can be effective and trials are under way to test drugs that act by reducing cytokine response, such as tocilizumab and sarilumab which bind interleukin 6 (IL-6), or anakinra which is the interleukin 1 receptor antagonist (IL-1). However, other drugs that block the cytokine cascade can also be considered. In this article we describe the scientific and molecular motivation for the use of drugs that act by modulating the hyperactive inflammatory system in severe patients suffering from SARS-CoV-2, considering in particular an old drug that has been in use for many years for other therapeutic indications such as colchicine, and that could be favorable to its use, with low cost and good tolerability.



PlumX Metrics


Download data is not yet available.


How to Cite

Vitiello, A., Ferrara, F., Pelliccia, C., Granata, G., & La Porta, R. (2020). Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia. Italian Journal of Medicine, 14(2), 88–94.

List of Cited By :

Crossref logo